Squarepoint Ops LLC Increases Stake in Insys Therapeutics Inc (NASDAQ:INSY)

Squarepoint Ops LLC increased its holdings in Insys Therapeutics Inc (NASDAQ:INSY) by 411.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,513 shares of the specialty pharmaceutical company’s stock after acquiring an additional 48,674 shares during the period. Squarepoint Ops LLC owned about 0.08% of Insys Therapeutics worth $212,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in INSY. ETF Managers Group LLC purchased a new stake in shares of Insys Therapeutics during the 4th quarter worth about $5,076,000. D. E. Shaw & Co. Inc. increased its holdings in shares of Insys Therapeutics by 158.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 512,444 shares of the specialty pharmaceutical company’s stock valued at $1,793,000 after acquiring an additional 314,264 shares during the last quarter. Vanguard Group Inc increased its holdings in shares of Insys Therapeutics by 4.7% during the 3rd quarter. Vanguard Group Inc now owns 2,661,324 shares of the specialty pharmaceutical company’s stock valued at $26,825,000 after acquiring an additional 119,776 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Insys Therapeutics by 4.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,661,324 shares of the specialty pharmaceutical company’s stock valued at $26,825,000 after acquiring an additional 119,776 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Insys Therapeutics by 2.8% during the 3rd quarter. BlackRock Inc. now owns 2,710,787 shares of the specialty pharmaceutical company’s stock valued at $27,325,000 after acquiring an additional 73,282 shares during the last quarter. 16.38% of the stock is owned by hedge funds and other institutional investors.

INSY traded down $0.39 during trading on Friday, hitting $3.60. The company’s stock had a trading volume of 912,120 shares, compared to its average volume of 427,891. The company has a market cap of $302.91 million, a price-to-earnings ratio of -2.59 and a beta of 2.43. Insys Therapeutics Inc has a 12 month low of $3.35 and a 12 month high of $11.65.

Insys Therapeutics (NASDAQ:INSY) last released its earnings results on Thursday, March 7th. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.08). Insys Therapeutics had a negative net margin of 151.79% and a negative return on equity of 1,430.52%. The firm had revenue of $16.36 million during the quarter, compared to analyst estimates of $17.93 million. On average, sell-side analysts forecast that Insys Therapeutics Inc will post -1.55 EPS for the current fiscal year.

A number of analysts have issued reports on the company. ValuEngine raised Insys Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Piper Jaffray Companies set a $4.00 price objective on Insys Therapeutics and gave the stock a “sell” rating in a research report on Friday, March 8th. Royal Bank of Canada reduced their price objective on Insys Therapeutics from $9.00 to $7.00 and set an “outperform” rating for the company in a research report on Friday, March 8th. Cantor Fitzgerald began coverage on Insys Therapeutics in a research report on Tuesday, January 22nd. They issued an “overweight” rating and a $4.40 price objective for the company. Finally, Janney Montgomery Scott set a $11.00 target price on Insys Therapeutics and gave the stock a “buy” rating in a research report on Saturday, January 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $7.28.

TRADEMARK VIOLATION WARNING: “Squarepoint Ops LLC Increases Stake in Insys Therapeutics Inc (NASDAQ:INSY)” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/11/insys-therapeutics-inc-insy-shares-bought-by-squarepoint-ops-llc.html.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc, a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Featured Article: Cost of Equity For A Business, Investors

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.